Yazar "Degertekin, H." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe 72 week data of the HIDIT-1 trial(Elsevier Science Bv, 2007) Wedemeyer, H.; Yurdaydin, C.; Dalekos, G.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.; Gurel, S.[Abstract Not Available]Öğe Evaluation of Hepatitis B Viraemia Levels in Patients with HBeAg-negative Chronic Hepatitis B Virus Infection(Sage Publications Ltd, 2012) Atay, A. E.; Seven, G.; Yalcin, K.; Pasa, S.; Degertekin, H.OBJECTIVES: To evaluate patients with chronic hepatitis B virus (HBV) infection and low-level viraemia in terms of determining HBV DNA cut-off values and levels of alanine aminotransferase (ALT) and other possible markers for discriminating between chronic hepatitis B e-antigen (HBeAg)-negative patients and hepatitis B surface antigen (HBsAg) inactive carriers. METHODS: HBV-infected patients who were HBeAg-negative with undetectable HBV DNA by standard hybridization assay and high (HBeAg-negative group, n = 81) or normal (HBsAg inactive carrier group, n = 77) ALT levels were enrolled. Quantitative polymerase chain reaction assay using a COBAS Amplicor HBV monitor test was performed to detect low HBV DNA levels. RESULTS: The HBV DNA level was found to be significantly higher in the HBeAg-negative chronic HBV group (mean +/- SD 94 477 +/- 167 528 copies/nil) compared with the HBsAg inactive carrier group (mean +/- SD 19 215 +/- 57 970 copies/ml). CONCLUSIONS: A low level of viral replication may persist in chronic HBV-infected patients who are HBeAg-negative, and the level of HBV DNA was higher in the HBeAg-negative group than in the inactive HBsAg carrier group. Necroinflammation also persisted in the HBeAg-negative group and these patients had a higher level of ALT than the inactive HBsAg carriers.Öğe A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis(Blackwell Publishing, 2007) Yurdaydin, C.; Bozkaya, H.; Karaaslan, H.; Oender, F. O.; Erkan, Oe. E.; Yalcin, K.; Degertekin, H.High dose interferon treatment for 1 year is the only established treatment for chronic hepatitis D, but it is associated with a high relapse rate after treatment discontinuation. In this study, patients were treated with 10 MU interferon alpha 2b, thrice weekly for 2 years. Twenty-three patients were recruited and 15 completed the 2-year treatment and 6 months follow-up periods. Treatment response was assessed biochemically [normal alanine aminotransferase (ALT)], virologically (undetectable hepatitis D virus RNA) and histologically (at least 2 point decrease in the Knodell score) at the end of treatment (EOT) and at the end of follow-up. Out of 15 patients who finished the 2-year treatment period, seven patients (47%) had a biochemical response but only two (13%) had a normal ALT after follow-up. ALT decreased from the baseline value of 143.1 +/- 121.7 (mean +/- SD) to 39.7 +/- 20.6 (P < 0.01) at EOT. Virological response was observed in six patients at EOT and in two patients at follow-up. Two patients lost hepatitis B surface antigen. Of the 12 patients with paired liver biopsies, a histological improvement was observed in eight patients. Interferon treatment leads to a complete or partial response in a substantial number of patients but 2 years of treatment does not appear to increase sustained response rates over 1 year treatment.Öğe Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the HEP-NET/International HDV Intervention Trial(Elsevier Science Bv, 2006) Zachou, K.; Yurdaydin, C.; Dienes, H. R.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Degertekin, H.[Abstract Not Available]
